- Home
- OKYO vs RADX Comparison
OKYO vs RADX Comparison
Compare OKYO & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- RADX
- Stock Information
- Founded
- OKYO 2007
- RADX 2021
- Country
- OKYO United Kingdom
- RADX Australia
- Employees
- OKYO N/A
- RADX N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- RADX
- Sector
- OKYO Health Care
- RADX
- Exchange
- OKYO Nasdaq
- RADX NYSE
- Market Cap
- OKYO 37.0M
- RADX 32.5M
- IPO Year
- OKYO 2022
- RADX N/A
- Fundamental
- Price
- OKYO $1.85
- RADX $4.65
- Analyst Decision
- OKYO Strong Buy
- RADX Strong Buy
- Analyst Count
- OKYO 1
- RADX 2
- Target Price
- OKYO $7.00
- RADX $13.50
- AVG Volume (30 Days)
- OKYO 198.3K
- RADX 16.7K
- Earning Date
- OKYO 06-06-2025
- RADX 02-26-2025
- Dividend Yield
- OKYO N/A
- RADX N/A
- EPS Growth
- OKYO N/A
- RADX N/A
- EPS
- OKYO N/A
- RADX N/A
- Revenue
- OKYO N/A
- RADX $204,609.00
- Revenue This Year
- OKYO N/A
- RADX N/A
- Revenue Next Year
- OKYO N/A
- RADX N/A
- P/E Ratio
- OKYO N/A
- RADX N/A
- Revenue Growth
- OKYO N/A
- RADX N/A
- 52 Week Low
- OKYO $0.81
- RADX $3.50
- 52 Week High
- OKYO $1.98
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- OKYO 62.66
- RADX N/A
- Support Level
- OKYO $1.70
- RADX N/A
- Resistance Level
- OKYO $1.98
- RADX N/A
- Average True Range (ATR)
- OKYO 0.18
- RADX 0.00
- MACD
- OKYO 0.03
- RADX 0.00
- Stochastic Oscillator
- OKYO 80.30
- RADX 0.00
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.